Intelligent Bio Solutions Inc. (INBS)

NCM – Real vaqt narxi. Valyuta: USD

2.25

+0.10 (4.65%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

2.18

-0.07 (-3.10%)

Bozordan keyin: Jun 26, 2026, 7:24 PM EDT

16.06.2026

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings

04.06.2026

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Conference Details Date: June 16-18, 2026 Location: Bellagio Hotel & Casino, Las Vegas Presentation Date and Time: Wednesday, June 17, 2026, at 8:00 – 8:30 AM PDT Presentation Location: Track 7 – Donatello 3 Registration: Interested investors can register to attend here Webcast: Viewable here Booth: 413 The Company will be participating in one-on-one investor meetings throughout the event.

02.06.2026

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment and data collection by the end of July, 2026 NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. The Company has partnered with nationwide clinical research site network, CenExel Clinical Research, Inc., to perform the study, which will evaluate the accuracy of the Intelligent Fingerprinting Drug Screening System when operated by intended end-users across multiple clinical sites.

13.05.2026

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update. "The third quarter marked another period of strong commercial execution and revenue growth," said Harry Simeonidis, President and CEO at INBS.

20.04.2026

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes

17.04.2026

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission

02.04.2026

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference testing NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its initial clinical Cut-off Study supporting the Company's FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The clinical Cut-off Study evaluated codeine detection cut-off levels in 40 adults, with full data analysis completed as planned by the end of March 2026.

Videolar

No Data

There is no data to display

Press-relizlar

16.06.2026

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings

04.06.2026

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

02.06.2026

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

13.05.2026

Intelligent Bio Solutions Inc. (INBS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Intelligent Bio Solutions Inc. (INBS)

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Videolar

No Data

Press-relizlar

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Videolar

No Data

Press-relizlar

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Search stocks

Intelligent Bio Solutions Inc. (INBS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Intelligent Bio Solutions Inc. (INBS)

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Videolar

No Data

Press-relizlar

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market

Videolar

No Data

Press-relizlar

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year